PMC9939440_01
Specific time points corresponding to the diagnostic and therapeutic process. SD, stable disease; PD, progressive disease.
fonc-13-1084681-g001.jpg
PMC9939440_01_fonc-13-1084681-g001.jpg
f1
We report the case of a 76-year-old woman (specific time points in  Figure 1 ) diagnosed in December 2016 with stage IV RAS BRAF wild-type, poorly differentiated transverse colon adenocarcinoma with subcutaneous, pleural, left axillary, and abdominal lymph-node involvement ( Figures 2A-D ).
Basal metastatic sites at diagnosis: primary tumor (PT), left axillary node (AN), pleural nodes (PlN), and peritoneal node (PeN) (A-D). Response to treatment after six courses: patient achieved response on primary tumor and all metastatic sites, except for the left axillary node (E-H).
fonc-13-1084681-g002.jpg
PMC9939440_01_fonc-13-1084681-g002.jpg
f2
We report the case of a 76-year-old woman (specific time points in  Figure 1 ) diagnosed in December 2016 with stage IV RAS BRAF wild-type, poorly differentiated transverse colon adenocarcinoma with subcutaneous, pleural, left axillary, and abdominal lymph-node involvement ( Figures 2A-D ). After six cycles, she reported a mixed response for a partial remission on metastatic sites but progressive disease on the axillary node ( Figures 2E-H ).
Pulmonary relapse (A, B). Complete response of lung metastases after reintroduction of chemotherapy (C, D).
fonc-13-1084681-g003.jpg
PMC9939440_01_fonc-13-1084681-g003.jpg
f3
On June 2018, CT scan showed lung progression for evidence of two new lesions ( Figures 3A, B ). During this period, disease stability and response on the new lung metastases were achieved ( Figures 3C, D ) and treatment was stopped temporarily for ocular toxicity (Grade 2, CTCAE 4.0) that was particularly bothersome for the patient.